RIGEL PHARMACEUTICALS

Latest clinical program signals indexed for RIGEL PHARMACEUTICALS.

1. GAVRETO ®(pralsetinib) capsules — Approved

   Jun 8, 2026
   Clinical update →

2. Ruxolitinib — Phase 2

   Jun 8, 2026
   Clinical update →

3. Olutasidenib — Phase 2

   Jun 8, 2026
   Clinical update →

4. Olutasidenib — Phase 2

   Jun 8, 2026
   Clinical update →

5. Olutasidenib Investigational Agent Administration — Phase 1

   Jun 8, 2026
   Clinical update →

6. Fostamatinib — Phase 2

   Jun 8, 2026
   Clinical update →

7. fostamatinib — Phase 2

   Jun 8, 2026
   Clinical update →

8. Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel) — Phase 1

   Jun 8, 2026
   Clinical update →

1. 2025-523158-15-00

   GAVRETO ®(pralsetinib) capsules

   Approved · active · small_molecule

   Patients with advanced or metastatic solid tumors

   CTIS ↗
2. NCT00115089

   R926112

   Phase 2 · completed · small_molecule

   Rhinitis, Allergic, Seasonal

   CT.gov ↗
3. NCT00326339

   R788

   Phase 2 · completed · small_molecule

   Rheumatoid Arthritis

   CT.gov ↗
4. NCT00446095

   fostamatinib

   Phase 2 · completed · small_molecule

   Lymphoma

   CT.gov ↗
5. NCT00665626

   Fostamatinib disodium (R935788)

   Phase 2 · completed · small_molecule

   Rheumatoid Arthritis

   CT.gov ↗
6. NCT00665925

   Fostamatinib disodium (R935788)

   Phase 2 · completed · small_molecule

   Rheumatoid Arthritis

   CT.gov ↗
7. NCT00706342

   Fostamatinib Disodium / R935788

   Phase 2 · completed · small_molecule

   Purpura, Thrombocytopenic, Idiopathic

   CT.gov ↗
8. NCT00752999

   Fostamatinib Disodium (R935788)

   Phase 2 · terminated · small_molecule

   Systemic Lupus Erythematosus

   CT.gov ↗
9. NCT00774787

   imiquimod 5% cream

   Approved · completed · small_molecule

   Actinic Keratoses

   CT.gov ↗
10. NCT00798096

    Fostamatinib Disodium

    Phase 2 · completed · small_molecule

    T Cell Lymphoma

    CT.gov ↗
11. NCT01591044

    Placebo

    Phase 2 · completed · small_molecule

    Asthma

    CT.gov ↗
12. NCT01597050

    R932333

    Phase 2 · completed · small_molecule

    Lupus Erythematosus, Discoid

    CT.gov ↗
13. NCT01733992

    R348 Ophthalmic Solution, 0.2%

    Phase 2 · completed · small_molecule

    Keratoconjunctivitis Sicca

    CT.gov ↗
14. NCT01900249

    R348 Ophthalmic Solution, 0.2%

    Phase 2 · completed · small_molecule

    Keratoconjunctivitis Sicca

    CT.gov ↗
15. NCT02040623

    R348 Ophthalmic Solution, 0.2%

    Phase 2 · completed · small_molecule

    Chronic Graft-versus-host Disease

    CT.gov ↗
16. NCT02076399

    Fostamatinib disodium

    Phase 3 · completed · small_molecule

    Immune Thrombocytopenic Purpura

    CT.gov ↗
17. NCT02076412

    Fostamatinib disodium

    Phase 3 · completed · small_molecule

    Immune Thrombocytopenic Purpura

    CT.gov ↗
18. NCT02077192

    Fostamatinib disodium

    Phase 3 · completed · small_molecule

    Immune Thrombocytopenic Purpura

    CT.gov ↗
19. NCT02112838

    Fostamatinib 150 mg

    Phase 2 · completed · small_molecule

    IGA Nephropathy

    CT.gov ↗
20. NCT02433236

    Fostamatinib Disodium tablet 100 mg

    Phase 2 · terminated · small_molecule

    IGA Nephropathy

    CT.gov ↗
21. NCT02612558

    Fostamatinib 150 mg bid

    Phase 2 · completed · small_molecule

    Warm Antibody Autoimmune Hemolytic Anemia

    CT.gov ↗
22. NCT03246074

    Fostamatinib 100 mg bid and Paclitaxel

    Phase 1 · completed · small_molecule

    Ovarian Cancer

    CT.gov ↗
23. NCT03764618

    Fostamatinib disodium

    Phase 3 · active · small_molecule

    Warm Antibody Autoimmune Hemolytic Anemia

    CT.gov ↗
24. NCT04138927

    Fostamatinib disodium

    Phase 3 · active · small_molecule

    Warm Antibody Autoimmune Hemolytic Anemia

    CT.gov ↗
25. NCT04543279

    Fostamatinib

    Phase 2 · terminated · small_molecule

    Myelofibrosis

    CT.gov ↗
26. NCT04581954

    Ruxolitinib

    Phase 2 · completed · small_molecule

    Coronavirus

    CT.gov ↗
27. NCT04629703

    Fostamatinib

    Phase 3 · completed · small_molecule

    Covid19

    CT.gov ↗
28. NCT05040698

    Fostamatinib

    Phase 2 · completed · small_molecule

    Hidradenitis Suppurativa

    CT.gov ↗
29. NCT05308264

    R906289 Monosodium (R289 Na)

    Phase 2 · active · small_molecule

    Low Risk Myelodysplastic Syndromes

    CT.gov ↗
30. NCT05848258

    LY3871801

    Phase 2 · completed · small_molecule

    Rheumatoid Arthritis

    CT.gov ↗
31. NCT06161974

    Olutasidenib + TMZ

    Phase 2 · active · small_molecule

    High Grade Glioma

    CT.gov ↗
32. NCT06233110

    Fostamatinib

    Phase 1 · active · small_molecule

    Chronic Graft Versus Host Disease

    CT.gov ↗
33. NCT06445959

    Olutasidenib

    Phase 2 · active · small_molecule

    Mutant IDH1 Inhibitor Olutasidenib

    CT.gov ↗
34. NCT06564207

    Placebo

    Phase 2 · active · small_molecule

    Acute Respiratory Distress Syndrome

    CT.gov ↗
35. NCT06566742

    Olutasidenib

    Phase 2 · active · small_molecule

    Myelodysplastic Syndromes

    CT.gov ↗
36. NCT06597734

    Olutasidenib

    Phase 2 · terminated · small_molecule

    Chronic Myelomonocytic Leukemia

    CT.gov ↗
37. NCT06639724

    Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)

    Phase 1 · active · other

    Pancreatic Ductal Adenocarcinoma (PDAC)

    CT.gov ↗
38. NCT06782542

    Olutasidenib

    Phase 2 · active · small_molecule

    Acute Myeloid Leukemia

    CT.gov ↗
39. NCT07032727

    Olutasidenib

    Phase 2 · active · small_molecule

    Targeted Therapy

    CT.gov ↗
40. NCT07130695

    Olutasidenib Investigational Agent Administration

    Phase 1 · active · small_molecule

    Acute Myeloid Leukemia

    CT.gov ↗
41. NCT07486713

    Olutasidenib

    Approved · active · small_molecule

    AML (Acute Myeloid Leukemia)

    CT.gov ↗